ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis.
Jamie S K Takayesu, Tian Xie, Jessica Aldous et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of first-generation nonsteroidal antiandrogens (NSAA) on overall survival (OS) and toxicity in patients with localized prostate cancer receiving androgen deprivation therapy (ADT) with radiation. The study found that while longer LHRHa duration improved OS, prolonging NSAA did not yield a significant OS benefit (≥6-month NSAA hazard ratio, 1.68, P = .02).
Key findings
- Prolonging NSAA duration did not significantly improve overall survival (hazard ratio, 1.68, P = .02).
- Longer NSAA duration was associated with higher odds of early ADT discontinuation (3-5 months odds ratio, 5.05, P = .03).
- No significant association was found between longer NSAA or LHRHa duration and other-cause mortality.
Why it matters
Understanding the effects of NSAA duration on survival and treatment adherence is crucial for optimizing prostate cancer management. This study suggests that extending NSAA may not provide survival benefits and could lead to increased treatment discontinuation.